The European Commission has finally launched its much-awaited joint evaluation of the EU pediatric and orphan drugs legislation as part of ongoing efforts to assess why the combined effects of these legal instruments have failed to deliver major therapeutic advances in diseases that are rare and/or unique in children.
Stakeholders have until Jan. 4, 2019 to respond to an online questionnaire concerning medicines for pediatric diseases that qualify...








